JP2017507911A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017507911A5 JP2017507911A5 JP2016545781A JP2016545781A JP2017507911A5 JP 2017507911 A5 JP2017507911 A5 JP 2017507911A5 JP 2016545781 A JP2016545781 A JP 2016545781A JP 2016545781 A JP2016545781 A JP 2016545781A JP 2017507911 A5 JP2017507911 A5 JP 2017507911A5
- Authority
- JP
- Japan
- Prior art keywords
- individual
- drugs
- antigen
- immunomodulatory composition
- immunomodulatory
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461924607P | 2014-01-07 | 2014-01-07 | |
| US61/924,607 | 2014-01-07 | ||
| PCT/IB2015/050108 WO2015104656A1 (en) | 2014-01-07 | 2015-01-07 | Immunomodulatory compositions and methods of use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017507911A JP2017507911A (ja) | 2017-03-23 |
| JP2017507911A5 true JP2017507911A5 (https=) | 2018-06-07 |
| JP6670244B2 JP6670244B2 (ja) | 2020-03-18 |
Family
ID=53523583
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016545781A Active JP6670244B2 (ja) | 2014-01-07 | 2015-01-07 | 免疫調節組成物及びその使用法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US10369205B2 (https=) |
| EP (1) | EP3092001B1 (https=) |
| JP (1) | JP6670244B2 (https=) |
| CN (1) | CN106102771B (https=) |
| AU (1) | AU2015205342B2 (https=) |
| CA (1) | CA2935511C (https=) |
| WO (1) | WO2015104656A1 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102193635B1 (ko) * | 2015-01-09 | 2020-12-21 | 이투빅스 코포레이션 | 복합 면역요법을 위한 방법 및 조성물 |
| WO2016172249A1 (en) | 2015-04-20 | 2016-10-27 | Etubics Corporation | Methods and compositions for combination immunotherapy |
| EP4480544A3 (en) * | 2015-08-25 | 2025-03-26 | Babita Agrawal | Immunomodulatory compositions andmethods of use thereof |
| CN108430482A (zh) * | 2015-11-10 | 2018-08-21 | 伊丽莎白·麦克纳 | 细胞氧化还原水平的控制 |
| CN112998905B (zh) | 2016-03-02 | 2024-05-24 | 巴德股份有限公司 | 栓塞防护篮装置 |
| WO2017201390A1 (en) * | 2016-05-19 | 2017-11-23 | The Regents Of The University Of Michigan | Novel adjuvant compositions |
| KR20190125481A (ko) * | 2017-03-17 | 2019-11-06 | 백심 아게 | 암의 면역요법을 위한 신규 pd-l1 표적화 dna 백신 |
| WO2018217764A1 (en) * | 2017-05-22 | 2018-11-29 | Kansas State University Research Foundation | Microbiome transplantation |
| CN109157651A (zh) * | 2018-09-06 | 2019-01-08 | 内蒙古科技大学包头医学院 | 具有免疫调节作用的组合物 |
| CN112569243A (zh) * | 2019-09-30 | 2021-03-30 | 神农医药科技有限公司 | 制备治疗阿尔茨海默病的药物 |
| EP3900736A1 (en) * | 2020-04-24 | 2021-10-27 | Klinikum der Universität München (KUM) | Composition comprising a dna-degrading enzyme for use in a method for the treatment of immunosuppression after acute tissue injury |
| EP3904884A1 (en) * | 2020-04-30 | 2021-11-03 | Heinrich-Pette-Institut | Method for predicting the course of a viral disease |
| CN115485565A (zh) * | 2020-04-30 | 2022-12-16 | 莱布尼茨实验病毒学研究所 | 用于预测病毒疾病的过程的方法 |
| US10973908B1 (en) | 2020-05-14 | 2021-04-13 | David Gordon Bermudes | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine |
| US12537071B1 (en) | 2020-07-22 | 2026-01-27 | David Gordon Bermudes | Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins |
| CN111956798B (zh) * | 2020-09-04 | 2023-03-03 | 江苏省农业科学院 | 用于猪伪狂犬灭活疫苗的复合免疫增强剂及其应用 |
| CN112375712A (zh) * | 2020-11-25 | 2021-02-19 | 昆明理工大学 | 一株乳酸乳球菌及其应用 |
| CN113413486B (zh) * | 2021-06-01 | 2022-05-10 | 中国科学院上海硅酸盐研究所 | 一种表面改性的聚醚醚酮材料及其制备方法和应用 |
| CA3254356A1 (en) * | 2022-04-07 | 2023-10-12 | Veru Inc. | METHODS OF TREATMENT OF VIRAL INFECTIONS OF INFLUENZA AND POXVIRUS |
| CN115975814B (zh) * | 2022-09-02 | 2025-11-04 | 南方医科大学 | 一种聚酮化合物及其制备方法与应用 |
| CN117323442B (zh) * | 2023-08-30 | 2024-05-03 | 广东医科大学 | 一种巨噬细胞靶向二氧化锰纳米系统的制备方法及其应用 |
| US12268717B1 (en) | 2024-03-01 | 2025-04-08 | Malireddy S. Reddy | Enhanced microbial therapeutic agents |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5614504A (en) | 1990-08-01 | 1997-03-25 | The University Of South Florida | Method of making inosine monophosphate derivatives and immunopotentiating uses thereof |
| US5514688A (en) | 1990-09-14 | 1996-05-07 | Merrell Dow Pharmaceuticals Inc. | Carbocyclic adenosine analogs useful as immunosuppressants |
| US5591748A (en) | 1991-06-07 | 1997-01-07 | Smithkline Beecham Corporation | Immunomodulatory azaspiranes |
| US5541193A (en) | 1991-09-05 | 1996-07-30 | Abbott Laboratories | Heterocycle-containing macrocyclic immunomodulators |
| US6210948B1 (en) | 1992-06-09 | 2001-04-03 | The University Of British Columbia | Expression and secretion of heterologous polypeptides from caulobacter |
| CA2090549C (en) | 1992-06-09 | 2008-01-15 | John Smit | Bacterial surface protein expression |
| US5976864A (en) | 1992-06-09 | 1999-11-02 | The University Of British Columbia | Expression and secretion of heterologous polypeptides from caulobacter |
| US5843936A (en) | 1996-06-28 | 1998-12-01 | Bernstein; Lawrence R. | Topical administration of azaspiranes to prevent or treat skin conditions associated with hyperproliferation of keratinocytes |
| IL129126A0 (en) | 1996-10-16 | 2000-02-17 | Icn Pharmaceuticals | Monocyclic l-nucleosides analogs and uses thereof |
| CA2363146A1 (en) * | 1999-02-22 | 2000-08-31 | Solomon Langermann | Caulobacter lps immunoadjuvant |
| ES2424131T3 (es) | 2001-03-27 | 2013-09-27 | Oncothyreon Inc. | Vacuna para modular respuestas inmunitarias entre T1 y T2 |
-
2015
- 2015-01-07 WO PCT/IB2015/050108 patent/WO2015104656A1/en not_active Ceased
- 2015-01-07 EP EP15735215.4A patent/EP3092001B1/en active Active
- 2015-01-07 AU AU2015205342A patent/AU2015205342B2/en active Active
- 2015-01-07 US US15/108,744 patent/US10369205B2/en active Active
- 2015-01-07 JP JP2016545781A patent/JP6670244B2/ja active Active
- 2015-01-07 CN CN201580011257.XA patent/CN106102771B/zh active Active
- 2015-01-07 CA CA2935511A patent/CA2935511C/en active Active
-
2019
- 2019-07-15 US US16/511,847 patent/US10946082B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017507911A5 (https=) | ||
| Hou et al. | Insights into vaccines for elderly individuals: from the impacts of immunosenescence to delivery strategies | |
| Coccia et al. | Cellular and molecular synergy in AS01-adjuvanted vaccines results in an early IFNγ response promoting vaccine immunogenicity | |
| Rhee et al. | Mucosal vaccine adjuvants update | |
| Hafner et al. | Particulate formulations for the delivery of poly (I: C) as vaccine adjuvant | |
| Littauer et al. | Stable incorporation of GM-CSF into dissolvable microneedle patch improves skin vaccination against influenza | |
| Cong et al. | Comparative efficacy of a multi-epitope DNA vaccine via intranasal, peroral, and intramuscular delivery against lethal Toxoplasma gondii infection in mice | |
| Gebril et al. | Optimizing efficacy of mucosal vaccines | |
| Keijzer et al. | Inactivated influenza vaccine adjuvanted with bacterium-like particles induce systemic and mucosal influenza A virus specific T-cell and B-cell responses after nasal administration in a TLR2 dependent fashion | |
| Nam et al. | An adjuvanted zoster vaccine elicits potent cellular immune responses in mice without QS21 | |
| Bowen et al. | Cholera toxin acts as a potent adjuvant for the induction of cytotoxic T-lymphocyte responses with non-replicating antigens | |
| Kim et al. | Inactivated eyedrop influenza vaccine adjuvanted with poly (I: C) is safe and effective for inducing protective systemic and mucosal immunity | |
| US20190105387A1 (en) | Peptide particle formulation | |
| Cossette et al. | Intranasal subunit vaccination strategies employing nanomaterials and biomaterials | |
| Afzal et al. | Structural engineering of flagellin as vaccine adjuvant: quest for the minimal domain of flagellin for TLR5 activation | |
| Shokouhi et al. | Vaccination with three tandem repeats of M2 extracellular domain fused to Leismania major HSP70 protects mice against influenza A virus challenge | |
| Gamvrellis et al. | Characterisation of local immune responses induced by a novel nano-particle based carrier-adjuvant in sheep | |
| Zhang et al. | Exosome co-delivery of a STING agonist augments immunogenicity elicited by CVB3 VP1 vaccine via promoting antigen cross-presentation of CD8+ DCs | |
| Savoji et al. | Formulation of HBsAg in Montanide ISA 51VG adjuvant: Immunogenicity study and monitoring long-lived humoral immune responses | |
| Yin et al. | Efficacy of modified levamisole adjuvant on inactivated virus vaccine | |
| Ramirez et al. | BALB/c mice vaccinated with Leishmania major ribosomal proteins extracts combined with CpG oligodeoxynucleotides become resistant to disease caused by a secondary parasite challenge | |
| Alpatova et al. | Adjuvant properties of cytokines in vaccination | |
| US20220257752A1 (en) | New use of cyclic dinucleotides | |
| Lawson et al. | Mucosal immune responses induced by transcutaneous vaccines | |
| Tahamtan et al. | An overview of different types of immune stimulating adjuvants and their application |